journal
MENU ▼
Read by QxMD icon Read
search

Diabetes, Obesity & Metabolism

journal
https://www.readbyqxmd.com/read/28105738/glucagon-like-peptide-1-agonists-and-risk-of-acute-pancreatitis-in-patients-with-type-2-diabetes
#1
Heidi Storgaard, Frederik Cold, Lise L Gluud, Tina Vilsbøll, Filip K Knop
Glucagon-like peptide-1 receptor agonist (GLP-1RAs) labels warn about acute pancreatitis (AP) and impose doctors to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo-controlled trials (RCTs) investigating the effect of GLP-1RAs in type 2 diabetes. We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees...
January 20, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28105735/observational-registry-of-basal-insulin-treatment-orbit-in-patients-with-type-2-diabetes-uncontrolled-with-oral-antihyperglycaemic-drugs-real-life-use-of-basal-insulin-in-china
#2
Linong Ji, Puhong Zhang, Dongshan Zhu, Xian Li, Jiachao Ji, Juming Lu, Xiaohui Guo, Weiping Jia, Jianping Weng, Yangfeng Wu, Wenying Yang, Dajin Zou, Zhiguang Zhou, Changyu Pan, Yan Gao, Satish K Garg
AIMS: To examine treatment patterns following basal insulin (BI) introduction in type 2 diabetes mellitus (T2DM) patients under real-world conditions across China. MATERIALS AND METHODS: Overall, 18,995 patients inadequately controlled [HbA1c ≥ 53 mmol/mol (7%)] with oral antihyperglycaemic drugs (OADs) and willing to receive BI treatment were registered at 209 hospitals and followed at baseline (visit 1), 3 months (visit 2), and 6 months (visit 3). Type of BI was initiated at physicians' discretion...
January 20, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28105731/liraglutide-effects-on-cardiovascular-risk-biomarkers-in-patients-with-type-2-diabetes-and-albuminuria-a-sub-analysis-of-a-randomised-placebo-controlled-double-blind-cross-over-trial
#3
Bernt Johan von Scholten, Frederik Persson, Signe Rosenlund, Jesper Eugen-Olsen, Tomasz Pielak, Jens Faber, Tine Willum Hansen, Peter Rossing
: We assessed the effects of liraglutide treatment on five cardiovascular risk biomarkers, reflecting different pathophysiology: 1) Tumour necrosis factor-alpha (TNF-alpha); 2) Soluble urokinase plasminogen activator receptor (suPAR); 3) Mid-regional pro-adrenomedullin (MR-proADM); 4) Mid-regional pro-atrial natriuretic peptide (MR-proANP); and 5) Copeptin, in type 2 diabetes patients with albuminuria. In a randomised, double-blind, placebo-controlled, cross-over trial we enrolled patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio (UACR) > 30 mg/g) and estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1...
January 20, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28098426/dapagliflozin-in-patients-with-type-1-diabetes-a-post-hoc-analysis-of-the-effect-of-insulin-dose-adjustments-on-24-hour-continuously-monitored-mean-glucose-and-fasting-beta-hydroxybutyrate-levels-from-a-phase-iia-pilot-study
#4
Robert R Henry, Paresh Dandona, Jeremy Pettus, Sunder Mudaliar, John Xu, Lars Hansen
AIMS: To investigate the effects of total daily insulin dose (TDD) reductions on 24-hour continuously monitored mean glucose and fasting beta-hydroxybutyrate (a marker for diabetic ketosis/ketoacidosis [DKA]) using patient-level data from a 14-day, pilot study of dapagliflozin in type 1 diabetes. MATERIALS AND METHODS: Exploratory correlation analysis was performed post-hoc to determine the relationship between change in TDD and a) 24-hour mean glucose (by continuous glucose monitoring) and b) fasting beta-hydroxybutyrate, in 70 patients with type 1 diabetes receiving insulin and dapagliflozin (1-, 2...
January 18, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28098425/cardiovascular-effects-of-glp-1-receptor-agonist-therapies-in-patients-with-type-1-diabetes
#5
EDITORIAL
Manfredi Rizzo, Ali A Rizvi, Giorgio Sesti
No abstract text is available yet for this article.
January 18, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28094472/outpatient-60-hour%C3%A2-day-and-night%C3%A2-glucose-control-with-dual-hormone%C3%A2-artificial-pancreas-single-hormone-artificial-pancreas-%C3%A2-or-sensor-augmented-pump-therapy-in-adults-with%C3%A2-type-1-diabetes-an-open-label-%C3%A2-randomised-crossover-controlled-trial
#6
Ahmad Haidar, Virginie Messier, Laurent Legault, Martin Ladouceur, Rémi Rabasa-Lhoret
AIMS: To assess whether the dual-hormone (insulin and glucagon) artificial pancreas reduces hypoglycemia compared to the single-hormone (insulin alone) artificial pancreas in outpatient settings during the day and night. MATERIAL AND METHODS: In a randomized, three-way, crossover trial, we compared the dual-hormone artificial pancreas, the single-hormone artificial pancreas, and sensor-augmented pump therapy (control) in 23 adults with type 1 diabetes. Each intervention was applied from 08 h00 Day 1 to 20 h00 Day 3 (60 hours) in outpatient free-living conditions...
January 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28094469/immunohistochemical-assessment-of-glucagon-like-peptide-1-receptor-glp-1r-expression-in-the-pancreas-of-patients-with-type-2-diabetes
#7
Rikke Kaae Kirk, Charles Pyke, Matthias G von Herrath, Jane Preuss Hasselby, Lars Pedersen, Pia Gottrup Mortensen, Lotte Bjerre Knudsen, Ken Coppieters
Glucagon-like peptide-1 (GLP-1) is an incretin hormone which stimulates insulin release and inhibits glucagon secretion from the pancreas in a glucose-dependent manner. Incretin-based therapies, consisting of GLP-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, are used for the treatment of T2D. Immunohistochemical studies for GLP-1R expression have previously been hampered by the use of unspecific polyclonal antibodies. This study used a new monoclonal antibody to assess GLP-1R expression in pancreatic tissue from 23 patients with T2D, including 7 with a DPP-4 inhibitor and 1 with a GLP-1R agonist treatment history...
January 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28094466/effects-of-beta-blockers-on-all-cause-mortality-in-patients-with-type-2-diabetes-and-coronary-heart-disease
#8
Tetsuro Tsujimoto, Takehiro Sugiyama, Hiroshi Kajio
AIMS: Although beta-blockers can prolong survival in patients with myocardial infarction (MI) and heart failure with reduced left ventricular ejection fraction (HFrEF), use of beta-blockers in patients with diabetes may cause hypoglycaemia and weight gain, which are associated with an increased risk of death and cardiovascular events. METHODS: Using the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial data, we performed Cox proportional hazards analysis to assess the effects of beta-blockers on all-cause mortality in 2,244 patients with type 2 diabetes who had stable coronary heart disease (CHD) with and without a prior history of MI/HFrEF...
January 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28093853/randomized-clinical-trial-comparing-the-efficacy-and-safety-of-treatment-with-the-once-weekly-dipeptidyl-peptidase-4-dpp-4-inhibitor-omarigliptin-or-the-once-daily-dpp-4-inhibitor-sitagliptin-in-patients-with-type-2-diabetes-inadequately-controlled-on-metformin
#9
Ronald Goldenberg, Ira Gantz, Paula J Andryuk, Edward A O'Neill, Keith D Kaufman, Eseng Lai, Yin Na Wang, Shailaja Suryawanshi, Samuel S Engel
AIM: To compare the efficacy and safety of the once-weekly oral dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes (T2DM) and inadequate glycaemic control on metformin. MATERIALS AND METHODS: Patients with T2DM with a glycated haemoglobin (HbA1c) concentration ≥6.5% to ≤9.0% while on a stable dose of metformin (≥1500 mg/d) were randomized in a double-blind manner to receive omarigliptin 25 mg once weekly (n = 322) or sitagliptin 100 mg once daily (n = 320)...
January 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28093841/effect-of-valsartan-on-kidney-outcomes-in-people-with-impaired-glucose-tolerance
#10
Gemma Currie, M Angelyn Bethel, Björn Holzhauer, Steven M Haffner, Rury R Holman, John J V McMurray
AIMS: Renin-angiotensin system blockers reduce the incidence and progression of microalbuminuria and the subsequent development of end-stage renal disease (ESRD) in patients with type 2 diabetes. We aimed to examine the effect of valsartan on kidney outcomes in patients with impaired glucose tolerance (IGT). METHODS: In a double-blind randomized trial, 9306 patients with IGT were assigned to valsartan (160 mg daily) or placebo. The co-primary endpoints were the development of diabetes and two composite cardiovascular outcomes...
January 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28083972/renal-safety-of-canagliflozin-a-sodium-glucose-co-transporter-2-inhibitor-in-patients-with-type-2-diabetes-mellitus
#11
Mehul Desai, Yshai Yavin, Dainius Balis, Don Sun, John Xie, William Canovatchel, Norm Rosenthal
The incidence of renal-related adverse events (AEs) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active- and placebo-controlled trials (N = 5,598) and in a 104-week study versus glimepiride (N = 1,450) was low and similar in canagliflozin and non-canagliflozin groups. In the study versus glimepiride, canagliflozin was associated with an initial acute decrease in estimated glomerular filtration rate (eGFR) that attenuated over time, while eGFR declined progressively over 104 weeks with glimepiride; the incidence of renal-related AEs with canagliflozin was generally stable over time, while the incidence with glimepiride increased over 104 weeks...
January 12, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28075066/efficacy-and-safety-of-fixed-dose-combination-therapy-alogliptin-plus-metformin-in-asian-patients-with-type-2-diabetes-a-phase-3-trial
#12
Linong Ji, Ling Li, Jian Kuang, Tao Yang, Dong-Jun Kim, Azidah Abdul Kadir, Chien-Ning Huang, Douglas Lee
This study evaluated the efficacy and safety of 26 weeks of twice-daily (BID) alogliptin + metformin fixed-dose combination (FDC) therapy in Asian patients with type 2 diabetes. Patients aged 18 - 75 years with hemoglobin A1c (HbA1c) 7.5 - 10.0% after ≥2 months of diet and exercise and a 4-week placebo run-in were enrolled. Eligible patients were randomized (1:1:1:1) to placebo, alogliptin 12.5 mg BID, metformin 500 mg BID, or alogliptin 12.5 mg plus metformin 500 mg FDC BID. The primary endpoint was change in HbA1c from baseline to end of treatment (Week 26)...
January 11, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28074635/physician-step-prescription-and-monitoring-to-improve-arterial-health-smarter-a-randomized-controlled-trial-in-type-2-diabetes-and-hypertension
#13
Kaberi Dasgupta, Ellen Rosenberg, Lawrence Joseph, Alexandra B Cooke, Luc Trudeau, Simon L Bacon, Deborah Chan, Mark Sherman, Rémi Rabasa-Lhoret, Stella S Daskalopoulou
AIMS: There are few strategies proven to enhance physical activity and cardiometabolic profiles in type 2 diabetes and hypertension. We examined the effects of physician-delivered step count prescriptions and monitoring. METHODS: Participants randomized to the active arm were provided with pedometers and recorded step counts. Over a 1-year period, their physicians reviewed their records and provided a written step count prescription at each clinic visit. The overall goal was a 3,000 step/day increase over 1-year (individualized rate of increase)...
January 11, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28058800/basal-rate-tests-24-h-fasts-performed-in-type-1-diabetic-subjects-with-either-absolute-fasting-or-snacks-containing-negligible-carbohydrate-amounts-result-in-similar-glucose-profiles-a-randomized-controlled-prospective-trial
#14
Maike Haase, Melanie Kahle, Martin Janert, Juris J Meier, Michael A Nauck
AIMS/HYPOTHESIS: Basal rate tests (24 h fasting periods) may be necessary to optimize basal insulin replacement in type 1 diabetes. It was the aim to prospectively compare allowing negligible carbohydrate snacks versus absolute fasting. METHODS: 20 patients with type 1 diabetes (age 48 ± 15 years; 9 women, 11 men; BMI 28.5 ± 4.5 kg/m(2) ; HbA1c 8.8 ± 2.0 % (73.0 ± 21.9 mmol/mol); insulin dose 0.69 ± 0.31 IU/kg body weight and day) participated in two basal rate tests lasting 24 h in random order with unchanged basal insulin replacement...
January 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28058779/dual-role-of-il-1%C3%AE-in-islet-amyloid-formation-and-its-%C3%AE-cell-toxicity-implications-in-type-2-diabetes-and-islet-transplantation
#15
Yoo Jin Park, Garth L Warnock, Ziliang Ao, Nooshin Safikhan, Mark Meloche, Ali Asadi, Timothy J Kieffer, Lucy Marzban
AIMS/HYPOTHESIS: Islet amyloid, formed by aggregation of human islet amyloid polypeptide (hIAPP), contributes to β-cell failure in type 2 diabetes, cultured and transplanted islets. We previously showed that biosynthetic hIAPP aggregates induce β-cell Fas upregulation and activation of the Fas apoptotic pathway. Here, we used cultured human and hIAPP-expressing mouse islets to investigate: (1) the role of IL-1β in amyloid-induced Fas upregulation; (2) the effects of IL-1β-induced β-cell dysfunction on proIAPP processing and amyloid formation...
January 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28058769/upper-and-or-lower-gastrointestinal-adverse-events-with-glp-1-receptor-agonists-incidences-and-consequences
#16
Michael Horowitz, Vanita R Aroda, Jenny Han, Elise Hardy, Chris K Rayner
AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with gastrointestinal adverse events (AEs), although type and frequency may differ across the class. We characterized gastrointestinal AEs with different GLP-1RAs. METHODS: Two retrospective intent-to-treat analyses of 6-month patient-level data were conducted. Data from three studies comparing exenatide once weekly (QW; n = 617) with exenatide twice daily (BID; n = 606) were pooled, and one (DURATION-6) comparing exenatide QW (n = 461) with liraglutide (n = 450) was analyzed separately...
January 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28058763/relationship-of-glycated-haemoglobin-and-reported-hypoglycaemia-to-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and-recent-acute-coronary-syndromes-the-examine-trial
#17
Simon R Heller, Richard M Bergenstal, William B White, Stuart Kupfer, George L Bakris, William C Cushman, Cyrus R Mehta, Steven E Nissen, Craig A Wilson, Faiez Zannad, Yuyin Liu, Noah M Gourlie, Christopher P Cannon
AIMS: To investigate relationships between glycated haemoglobin (HbA1c) and reported hypoglycaemia and risk of major adverse cardiovascular (CV) events (MACE). METHODS: The EXAMINE trial randomized 5380 patients in 49 countries with type 2 diabetes (T2DM) and a recent acute coronary syndrome (ACS) to double-blind treatment with alogliptin or placebo in addition to standard of care. We used Cox proportional hazards models to analyze relationships among MACE, HbA1c levels and hypoglycaemia events...
January 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28058753/effect-of-gemigliptin-on-glycemic-variability-in-patients-with-type-2-diabetes
#18
Se E Park, Byung W Lee, Jae H Kim, Woo J Lee, Jae H Cho, Chang H Jung, Seung H Lee, Sunghwan Suh, Gwong C Hur, Sung H Kim, Young H Jang, Cheol Y Park
The aim of this study was to evaluate the effect of gemigliptin vs sitagliptin or glimepiride as initial combination therapy with metformin on glycemic variability and to assess the correlation between glycemic variability reduction and the dipeptidyl peptidase-4 (DPP-4) inhibition in patients with type 2 diabetes. This multicenter, randomized, active-controlled, open-label exploratory study included 69 patients with HbA1c >7.5%. Subjects were randomized to receive gemigliptin 50 mg (n = 24), sitagliptin 100 mg (n = 23), or glimepiride 2 mg (n = 22) for 12 weeks...
January 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28058750/efficacy-and-safety-of-adding-evogliptin-versus-sitagliptin-in-metformin-treated-patients-with-type-2-diabetes-a-24-week-randomised-controlled-trial-with-open-label-extension
#19
Sang-Mo Hong, Cheol-Young Park, Dong-Min Hwang, Kyung Ah Han, Chang Beom Lee, Choon Hee Chung, Kun-Ho Yoon, Ji-Oh Mok, Kyong Soo Park, Sung-Woo Park
AIMS: This trial consisted of a 24-week multicenter, randomised, double-blind, double-dummy, active-controlled study and a 52-week open label extension study to assess the efficacy and safety of evogliptin, a novel dipeptidyl peptidase-4 inhibitor, compared to sitagliptin in patients with type 2 diabetes who have inadequate glycaemic control with metformin alone. MATERIALS AND METHODS: Adult type 2 diabetes mellitus patients (N = 222) with HbA1c 6.5-11% on stable metformin doses (≥1000 mg/day) were randomised 1:1 to add-on 5 mg evogliptin (N = 112) or 100 mg sitagliptin (N = 110) once daily for 24 weeks...
January 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28026912/efficacy-and-safety-of-gemigliptin-a-dipeptidyl-peptidase-4-inhibitor-in-patients-with-type-2-diabetes-mellitus-inadequately-controlled-with-combination-treatment-of-metformin-and-sulfonylurea-a-24-week-multicenter-randomized-double-blind-placebo-controlled
#20
Chang Ho Ahn, Kyung Ah Han, Jae Myung Yu, Joo Young Nam, Kyu Jeung Ahn, Tae Keun Oh, Hyoung Woo Lee, Dae Ho Lee, Jaetaek Kim, Choon Hee Chung, Tae Sun Park, Byung Joon Kim, Seok Won Park, Hyeong Kyu Park, Kwang Jae Lee, Sang-Wook Kim, Jeong Hyun Park, Kwan Pyo Ko, Chong Hwa Kim, Hyunjin Lee, Hak Chul Jang, Kyong Soo Park
AIMS: To assess the efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, added to metformin and sulfonylurea in patients with type 2 diabetes. MATERIALS AND METHODS: We conducted a randomized, double-blind, placebo-controlled trial in 219 Korean patients inadequately controlled with metformin and glimepiride. Patients were randomized to gemigliptin 50 mg once daily or placebo added to metformin and glimepiride. The primary endpoint was the change in hemoglobin A1c (HbA1c) from baseline to week 24...
December 27, 2016: Diabetes, Obesity & Metabolism
journal
journal
34603
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"